Navigation Links
Anthera Presents Data on Varespladib at ATVB Meeting
Date:4/17/2008

SAN MATEO, Calif., April 17 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that Anthera scientists and collaborators have released data from the Varespladib (A-002) clinical and pre-clinical programs at the Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Annual Conference in Atlanta, Georgia, held on April 16-18, 2008. Anthera has completed Phase II trials in Varespladib for the treatment of coronary heart disease.
Posters include:

-- Effects of a Selective Secretory Phospholipase A2 Inhibitor on

Low-Density Lipoproteins in CHD Patients with Diabetes.

-- The Synergistic Inhibition of Atherogenesis in ApoE-/- Mice Between

Pravastatin and the sPLA2 Inhibitor Varespladib (A-002).

"We are pleased to see the synergistic effect of Varespladib with statins on plaque reduction, composition and stability in a well established model of atherosclerosis," said Joaquim Trias, Ph.D., Senior Vice President of Preclinical Development at Anthera Pharmaceuticals, Inc.

"Along with the Phase II PLASMA data presented at ACC earlier this year, today's announcement gives us added confidence as we move the Varespladib clinical program forward," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "These findings further support our clinical development program as we begin Phase III clinical trials in patients with acute coronary syndromes where inflammation, atherosclerosis and cholesterol levels are highly correlated with outcomes."

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co. Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com

INVESTOR AND MEDIA CONTACT:

Anne Bowdidge

(650) 218-6900

pr@anthera.com


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Pharmaceuticals Forms Scientific Advisory Board
2. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
3. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
4. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
5. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
6. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
7. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
8. SGX Presents Preclinical MET Data at AACR
9. ARIUS presents new findings for anti-cancer antibody programs at AACR
10. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
11. MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... BOSTON , Feb. 9, 2016 ... a data-driven, biological research approach, has announced the ... Financial Officer and Chief Operating Officer. Haddock brings ... corporate finance, including 12 years in senior financial ... global experience in business organizational management. ...
(Date:2/8/2016)... 8, 2016 --> ... an innovation-driven oncology company developing next generation cancer ... today announced that chairman emeritus of Tata Sons ... the company as part of the first close ... investors Navam Capital and Aarin Capital. ...
(Date:2/8/2016)... ... 2016 , ... Bulk food product inspection systems are specifically ... of the production process. Despite frequently inspecting loose product prior to packaging, product ... as sacks of dry powders. , Mettler-Toledo Product Inspection's brand-new white paper entitled ...
(Date:2/8/2016)... BATH, England , February 8, 2016 ... Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care ... approval to CE Mark its Chlamydia trachomatis (CT) test to ... requirements of the IVD Directive (98/79/EC), the CT test is ... --> --> The launch of the ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 This BCC Research report ... by reviewing the recent advances in high throughput ... the field forward. Includes forecast through 2019. ... challenges and opportunities that exist in the bioinformatic ... developers, as well as IT and bioinformatics service ...
(Date:2/1/2016)... BURNABY, Canada , February 1, 2016 ... new technological advancements to drive global touchfree intuitive gesture ...   --> Rising sales of consumer electronics ... intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ...
(Date:1/25/2016)... Pa. , Jan. 25, 2016   Unisys Corporation ... system at John F. Kennedy (JFK) International Airport, New ... Protection (CBP) identify imposters attempting to enter the ... not belong to them. pilot testing of the ... initially at three terminals at JFK during January 2016. --> ...
Breaking Biology News(10 mins):